ArticleEuropean journal of clinical investigation2008
Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.
Article in European journal of clinical investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Deferasirox for managing iron overload in people with myelodysplastic syndrome.The Cochrane database of systematic reviews · 2014Pooled it
- Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.Advances in therapy · 2015Trial
- Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.Haematologica · 2012Trial
- Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.Haematologica · 2010Trial
- Article
- Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".American journal of hematology · 2019Review
- Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.American journal of hematology · 2017Review
- Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.Drugs & aging · 2015Article
- Deferasirox in a refractory anemia after other treatment options: case report and literature review.Clinical case reports · 2015Article
- 10th anniversary of the Austrian MDS Platform: aims and ongoing projects.Wiener klinische Wochenschrift · 2015Article
- Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.Blood · 2014Review
- Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.International journal of hematology · 2014Article
- Plasma levels of aminothiols, nitrite, nitrate, and malondialdehyde in myelodysplastic syndromes in the context of clinical outcomes and as a consequence of iron overload.Oxidative medicine and cellular longevity · 2014Article
- Myelodysplastic syndromes: diagnosis, prognosis, and treatment.Deutsches Arzteblatt international · 2013Review
- Iron chelation therapy in myelodysplastic syndromes: where do we stand?Expert review of hematology · 2013Review
- The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.Annals of hematology · 2012Review
- Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.Drugs · 2011Review
- Iron chelation therapy in myelodysplastic syndromes.Advances in hematology · 2010Article
- [Individualized management and therapy of myelodysplastic syndromes].Wiener klinische Wochenschrift · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transfusion-related morbidity is an emerging challenge in chronically transfused patients with low-risk myelodysplastic syndromes (MDS). In these patients, transfusion-induced iron overload may represent a leading medical problem. However, although iron-chelating drugs are available, little is known about optimal diagnostic tools, predisposing factors, and the optimal management of these patients. In the current article, we provide recommendations for the diagnosis, prevention and treatment of iron overload in MDS and propose treatment response criteria. Consensus criteria and resulting recommendations were discussed and formulated by members of the MDS platform of the Austrian Society of Haematology and Oncology in a series of meetings and conferences in 2006 and 2007. These recommendations should facilitate and assist in recognition of iron overload, selection of patients, timing of treatment, drug selection and the measurement of treatment responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.